{ "labelLang" : "hun", "responseDate" : "2024-03-28 12:10", "content" : { "otype" : "JournalArticle", "mtid" : 31310604, "status" : "VALIDATED", "published" : true, "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-02-02T08:30:07.415+0000", "lastModified" : "2023-02-02T08:26:31.318+0000", "created" : "2020-05-12T08:17:06.297+0000", "creator" : { "otype" : "Author", "mtid" : 10011643, "link" : "/api/author/10011643", "label" : "Mócsai Attila (Élettan, sejtbiológia)", "familyName" : "Mócsai", "givenName" : "Attila", "published" : true, "oldId" : 10011643, "snippet" : true }, "lastDuplumOK" : "2023-02-02T08:26:22.509+0000", "lastDuplumSearch" : "2023-02-02T08:26:22.509+0000", "validated" : "2023-02-02T08:26:31.580+0000", "validator" : { "otype" : "Admin", "mtid" : 10026589, "link" : "/api/admin/10026589", "label" : "Tichy Rita (SE_KK_Admin5_TR, admin)", "familyName" : "Tichy", "givenName" : "Rita", "published" : true, "oldId" : 10026589, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Zhao, Y.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 91626985, "link" : "/api/authorship/91626985", "label" : "Zhao, Y.", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : false, "familyName" : "Zhao", "givenName" : "Y.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91626986, "link" : "/api/authorship/91626986", "label" : "Rahmy, S.", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Rahmy", "givenName" : "S.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91626987, "link" : "/api/authorship/91626987", "label" : "Liu, Z.", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Liu", "givenName" : "Z.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91626988, "link" : "/api/authorship/91626988", "label" : "Zhang, C.", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Zhang", "givenName" : "C.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91626989, "link" : "/api/authorship/91626989", "label" : "Lu, X. ✉", "listPosition" : 5, "share" : 0.0, "first" : false, "last" : true, "corresponding" : true, "familyName" : "Lu", "givenName" : "X.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Rational targeting of immunosuppressive neutrophils in cancer", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 16908022, "link" : "/api/publicationidentifier/16908022", "label" : "DOI: 10.1016/j.pharmthera.2020.107556", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/j.pharmthera.2020.107556", "realUrl" : "https://doi.org/10.1016/j.pharmthera.2020.107556", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17366417, "link" : "/api/publicationidentifier/17366417", "label" : "WoS: 000541079600003", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/WOS:@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000541079600003", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/WOS:000541079600003", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16908021, "link" : "/api/publicationidentifier/16908021", "label" : "Scopus: 85084244292", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85084244292", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85084244292", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 19042365, "link" : "/api/publicationidentifier/19042365", "label" : "PubMed: 32343986", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "32343986", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32343986&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 3624, "link" : "/api/journal/3624", "label" : "PHARMACOLOGY & THERAPEUTICS 0163-7258 1879-016X", "pIssn" : "0163-7258", "eIssn" : "1879-016X", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 3624, "snippet" : true }, "volume" : "212", "internalId" : "107556", "firstPageOrInternalIdForSort" : "107556", "pageLength" : 13, "publishedYear" : 2020, "abstractText" : "Neutrophils, the most abundant circulating leukocytes in human, play an indispensable role in the innate immune response to microbial infections. However, the contribution of tumor-associated neutrophils (TANs) to cancer progression and tumor immunity has been a matter of debate for decades. A higher neutrophil-to-lymphocyte ratio is associated with adverse overall survival in many solid tumors. Preclinical evidence exists to support both anti-tumor and pro-tumor activities of TANs, and TANs employ diverse mechanisms to influence tumor progression and metastasis. Here, we focus our review on the immunosuppressive mechanism of TANs and highlight how neutrophils can operate to dampen both innate and adaptive immunity to promote tumorigenesis. Here we discuss the intriguing and sometimes controversial connection between TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSCs). The molecular mechanisms underlying neutrophils' role in immunosuppression provide potential therapeutic targets for cancer treatment, either as monotherapies or as a part of combinatorial regimens. Therefore, we also highlight a number of neutrophil-targeting approaches that may improve the efficacy of current anticancer therapies, especially cancer immunotherapy. Currently interest is surging in the understanding and targeting of immunosuppressive neutrophils, with the goal of developing novel therapeutic strategies in the battle against cancer. © 2020 Elsevier Inc.", "keywords" : [ { "otype" : "Keyword", "mtid" : 4581, "link" : "/api/keyword/4581", "label" : "neutrophil", "published" : true, "oldId" : 4581, "snippet" : true }, { "otype" : "Keyword", "mtid" : 14256, "link" : "/api/keyword/14256", "label" : "immunotherapy", "published" : true, "oldId" : 14256, "snippet" : true }, { "otype" : "Keyword", "mtid" : 16812, "link" : "/api/keyword/16812", "label" : "immunosuppression", "published" : true, "oldId" : 16812, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1113033, "link" : "/api/keyword/1113033", "label" : "Tumor microenvironment", "published" : true, "oldId" : 1113033, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1502940, "link" : "/api/keyword/1502940", "label" : "Immuno-oncology", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 2010770, "link" : "/api/keyword/2010770", "label" : "PMN-MDSC", "published" : true, "snippet" : true } ], "digital" : true, "printed" : true, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-02-02", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 1, "citedCount" : 1, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10873711, "link" : "/api/sjrrating/10873711", "label" : "sjr:D1 (2020) Scopus - Pharmacology (medical) PHARMACOLOGY & THERAPEUTICS 0163-7258 1879-016X", "listPos" : 2, "rankValue" : 0.0, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2736, "link" : "/api/classificationexternal/2736", "label" : "Scopus - Pharmacology (medical)", "published" : true, "oldId" : 2736, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "referenceList" : "Albeituni, S.H., Ding, C., Liu, M., Hu, X., Luo, F., Kloecker, G., Yan, J., Yeast-derived particulate β-Glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing Polymorphonuclear MDSC apoptosis and Monocytic MDSC differentiation to APC in cancer (2016) Journal of Immunology (Baltimore, Md.: 1950), 196, pp. 2167-2180 ;\n Albrengues, J., Shields, M.A., Ng, D., Park, C.G., Ambrico, A., Poindexter, M.E., Egeblad, M., Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice (2018) Science, 361, p. 1353 ;\n Andrews, L.P., Yano, H., Vignali, D.A.A., Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups (2019) Nature Immunology, 20, pp. 1425-1434 ;\n Andzinski, L., Wu, C.F., Lienenklaus, S., Kroger, A., Weiss, S., Jablonska, J., Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-beta (2015) International Journal of Cancer, 136, pp. 572-583 ;\n Bannai, S., Transport of cystine and cysteine in mammalian cells (1984) Biochimica et Biophysica Acta, 779, pp. 289-306 ;\n Basu, S., Hodgson, G., Katz, M., Dunn, A.R., Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation (2002) Blood, 100, pp. 854-861 ;\n Bauer, R., Udonta, F., Wroblewski, M., Ben-Batalla, I., Santos, I.M., Taverna, F., Loges, S., Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy (2018) Cancer Research, 78, pp. 3220-3232 ;\n Bausch, D., Pausch, T., Krauss, T., Hopt, U.T., Fernandez-del-Castillo, C., Warshaw, A.L., Keck, T., Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma (2011) Angiogenesis, 14, pp. 235-243 ;\n Beer, T.M., Kwon, E.D., Drake, C.G., Fizazi, K., Logothetis, C., Gravis, G., Gerritsen, W., Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer (2017) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, pp. 40-47 ;\n Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Hanahan, D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) Nature Cell Biology, 2, pp. 737-744 ;\n Bosiljcic, M., Cederberg, R.A., Hamilton, M.J., LePard, N.E., Harbourne, B.T., Collier, J.L., Bennewith, K.L., Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs (2019) Breast Cancer Research, 21, p. 103 ;\n Bronstein-Sitton, N., Cohen-Daniel, L., Vaknin, I., Ezernitchi, A.V., Leshem, B., Halabi, A., Baniyash, M., Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function (2003) Nature Immunology, 4, pp. 957-964 ;\n Bruchard, M., Mignot, G., Derangere, V., Chalmin, F., Chevriaux, A., Vegran, F., Ghiringhelli, F., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth (2013) Nature Medicine, 19, pp. 57-64 ;\n Cadoo, K.A., Meyers, M.L., Burger, R.A., Armstrong, D.K., Penson, R.T., Gordon, M.S., Matulonis, U.A., A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC) (2019) Journal of Clinical Oncology, 37 ;\n Cao, Y., Feng, Y., Zhang, Y., Zhu, X., Jin, F., L-arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo (2016) BMC Cancer, 16, p. 343 ;\n Carmeliet, P., VEGF as a key mediator of angiogenesis in cancer (2005) Oncology, 69, pp. 4-10 ;\n Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature, 407, pp. 249-257 ;\n Casbon, A.J., Reynaud, D., Park, C., Khuc, E., Gan, D.D., Schepers, K., Werb, Z., Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils (2015) Proceedings of the National Academy of Sciences of the United States of America, 112, pp. E566-E575 ;\n Chao, T., Furth, E.E., Vonderheide, R.H., CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma (2016) Cancer Immunology Research, 4, pp. 968-982 ;\n Cheng, Y., Ma, X.L., Wei, Y.Q., Wei, X.W., Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases (2019) Biochimica Et Biophysica Acta. Reviews on Cancer, 1871, pp. 289-312 ;\n Christmas, B.J., Rafie, C.I., Hopkins, A.C., Scott, B.A., Ma, H.S., Cruz, K.A., Roussos Torres, E.T., Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs (2018) Cancer Immunology Research, 6, pp. 1561-1577 ;\n Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.S., de Visser, K.E., IL-17-producing gammadelt T cells and neutrophils conspire to promote breast cancer metastasis (2015) Nature, 522, pp. 345-348 ;\n Coffelt, S.B., Wellenstein, M.D., de Visser, K.E., Neutrophils in cancer: neutral no more (2016) Nature Reviews. Cancer, 16, pp. 431-446 ;\n Condamine, T., Dominguez, G.A., Youn, J.I., Kossenkov, A.V., Mony, S., Alicea-Torres, K., Gabrilovich, D.I., Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients (2016) Sci Immunol, p. 1 ;\n Corzo, C.A., Cotter, M.J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Gabrilovich, D.I., Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells (2009) Journal of Immunology, 182, pp. 5693-5701 ;\n De Sanctis, F., Sandri, S., Ferrarini, G., Pagliarello, I., Sartoris, S., Ugel, S., Bronte, V., The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment (2014) Frontiers in Immunology, 5 ;\n Derouet, M., Thomas, L., Cross, A., Moots, R.J., Edwards, S.W., Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1 (2004) The Journal of Biological Chemistry, 279, pp. 26915-26921 ;\n Deryugina, E.I., Bekes, E.M., Schweighofer, B., Kupriyanova, T.A., Quigley, J.P., Tumor-recruited neutrophils and their TIMP-free MMP-9 determine coordinately the levels of tumor angiogenesis and efficiency of malignant cell dissemination (2011) Clinical & Experimental Metastasis, 28, pp. 168-169 ;\n Deryugina, E.I., Zajac, E., Juncker-Jensen, A., Kupriyanova, T.A., Welter, L., Quigley, J.P., Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment (2014) Neoplasia, 16, pp. 771-788 ;\n Devi, S., Wang, Y., Chew, W.K., Lima, R., N, A.G., Mattar, C.N., (2013), pp. 2321-2336. , … Ng, L. G. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. Journal of Experimental Medicine, 210 ;\n Eash, K.J., Greenbaum, A.M., Gopalan, P.K., Link, D.C., CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow (2010) The Journal of Clinical Investigation, 120, pp. 2423-2431 ;\n El Rayes, T., Catena, R., Lee, S., Stawowczyk, M., Joshi, N., Fischbach, C., Mittal, V., Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1 (2015) Proceedings of the National Academy of Sciences of the United States of America, 112, pp. 16000-16005 ;\n Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., Ullenhag, G., Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer (2016) Journal of Translational Medicine, 14, p. 282 ;\n Fahey, E., Doyle, S.L., IL-1 family cytokine regulation of vascular permeability and angiogenesis (2019) Frontiers in Immunology, 10 ;\n Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (2014) Nature Reviews. Drug Discovery, 13, pp. 673-691 ;\n Feng, S., Cheng, X., Zhang, L., Lu, X., Chaudhary, S., Teng, R., Lu, X., Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers (2018) Proceedings of the National Academy of Sciences of the United States of America, 115, pp. 10094-10099 ;\n Ferrone, S., Whiteside, T.L., Tumor microenvironment and immune escape (2007) Surgical Oncology Clinics of North America, 16, p. 755 ;\n Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Umansky, V., Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression (2018) Frontiers in Immunology, 9, p. 398 ;\n Formenti, S.C., Lee, P., Adams, S., Goldberg, J.D., Li, X., Xie, M.W., McBride, W.H., Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer (2018) Clinical Cancer Research, 24, pp. 2493-2504 ;\n Fridlender, Z.G., Sun, J., Kim, S., Kappor, V., Cheng, G., Ling, L., Albelda, S.M., Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN (2009) Cancer cell, 16, pp. 183-194 ;\n Fuchs, T.A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Zychlinsky, A., Novel cell death program leads to neutrophil extracellular traps (2007) The Journal of Cell Biology, 176, pp. 231-241 ;\n Gabrilovich, D.I., Myeloid-Derived Suppressor Cells (2017) Cancer Immunology Research, 5, pp. 3-8 ;\n Geiger, R., Rieckmann, J.C., Wolf, T., Basso, C., Feng, Y.H., Fuhrer, T., Lanzavecchia, A., L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity (2016) Cell, 167, p. 829 ;\n Giese, M.A., Hind, L.E., Huttenlocher, A., Neutrophil plasticity in the tumor microenvironment (2019) Blood, 133, pp. 2159-2167 ;\n Gil, M., Komorowski, M.P., Seshadri, M., Rokita, H., McGray, A.J.R., Opyrchal, M., Kozbor, D., CXCL12/CXCR4 blockade by Oncolytic Virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells (2014) Journal of Immunology, 193, pp. 5327-5337 ;\n Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O'Donnell, J.S., Szczepanski, S., Holzel, M., Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy (2017) Immunity, 47 (789-802) ;\n Glozak, M.A., Sengupta, N., Zhang, X., Seto, E., Acetylation and deacetylation of non-histone proteins (2005) Gene, 363, pp. 15-23 ;\n Gmunder, H., Eck, H.P., Droge, W., Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones (1991) European Journal of Biochemistry, 201, pp. 113-117 ;\n Gomez-Cambronero, J., Horn, J., Paul, C.C., Baumann, M.A., Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: Involvement of the ribosomal p70 S6 kinase signaling pathway (2003) Journal of Immunology, 171, pp. 6846-6855 ;\n Greene, S., Robbins, Y., Mydlarz, W.K., Huynh, A.P., Schmitt, N.C., Friedman, J., Allen, C., Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models (2019) Clinical Cancer Research, 26, pp. 1420-1431 ;\n Groth, C., Hu, X.Y., Weber, R., Fleming, V., Altevogt, P., Utikal, J., Umansky, V., Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression (2019) British Journal of Cancer, 120, pp. 16-25 ;\n Hidalgo, A., Chilvers, E.R., Summers, C., Koenderman, L., The neutrophil life cycle (2019) Trends in Immunology, 40, pp. 584-597 ;\n Holmgaard, R.B., Schaer, D.A., Li, Y., Castaneda, S.P., Murphy, M.Y., Xu, X., Driscoll, K.E., Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade (2018) Journal for Immunotherapy of Cancer, 6, p. 47 ;\n Hong, C.W., Current understanding in neutrophil differentiation and heterogeneity (2017) Immune Netw, 17, pp. 298-306 ;\n Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., Chen, S.H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host (2006) Cancer Research, 66, pp. 1123-1131 ;\n Huo, X., Li, H., Li, Z., Yan, C., Agrawal, I., Mathavan, S., Gong, Z., Transcriptomic profiles of tumor-associated neutrophils reveal prominent roles in enhancing angiogenesis in liver tumorigenesis in zebrafish (2019) Scientific Reports, 9, p. 1509 ;\n Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., Gabrilovich, D., Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer (2013) Cancer immunology, immunotherapy: CII, 62, pp. 909-918 ;\n Isambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Ghiringhelli, F., Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): A single-arm phase 2 study (2018) Oncoimmunology, 7 ;\n Isles, H.M., Herman, K.D., Robertson, A.L., Loynes, C.A., Prince, L.R., Elks, P.M., Renshaw, S.A., The CXCL12/CXCR4 signaling axis retains neutrophils at inflammatory sites in zebrafish (2019) Frontiers in Immunology, 10 ;\n Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E.Y., Pinter, M., Fukumura, D., Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer (2017) Proceedings of the National Academy of Sciences of the United States of America, 114, pp. 10455-10460 ;\n Kanterman, J., Sade-Feldman, M., Biton, M., Ish-Shalom, E., Lasry, A., Goldshtein, A., Baniyash, M., Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes (2014) Cancer Research, 74, pp. 6022-6035 ;\n Kargl, J., Zhu, X., Zhang, H., Yang, G.H.Y., Friesen, T.J., Shipley, M., Houghton, A.M., Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC (2019) JCI insight, 4 ;\n Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Giannelli, G., A phase 2 study of Galunisertib (TGF-beta1 receptor type I inhibitor) and Sorafenib in patients with advanced hepatocellular carcinoma (2019) Clinical and Translational Gastroenterology, 10 ;\n Killock, D., Targeting MDSCs with LXR agonists (2018) Nature Reviews Clinical Oncology, 15, pp. 200-201 ;\n Kim, H.K., Sierra, M.D., Williams, C.K., Gulino, A.V., Tosato, G., G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells (2006) Blood, 108, pp. 812-820 ;\n Kim, K., Skora, A.D., Li, Z., Liu, Q., Tam, A.J., Blosser, R.L., Zhou, S., Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells (2014) Proceedings of the National Academy of Sciences of the United States of America, 111, pp. 11774-11779 ;\n Kohler, A., De Filippo, K., Hasenberg, M., van den Brandt, C., Nye, E., Hosking, M.P., Gunzer, M., G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands (2011) Blood, 117, pp. 4349-4357 ;\n Kolaczkowska, E., Kubes, P., Neutrophil recruitment and function in health and inflammation (2013) Nature Reviews. Immunology, 13, pp. 159-175 ;\n Kurzrock, R., Sherman, S.I., Ball, D.W., Forastiere, A.A., Cohen, R.B., Mehra, R., Salgia, R., Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer (2011) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, pp. 2660-2666 ;\n Kwilas, A.R., Ardiani, A., Donahue, R.N., Aftab, D.T., Hodge, J.W., Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine (2014) Journal of Translational Medicine, 12, p. 294 ;\n Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J.M., Investigators, C., Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial (2014) The Lancet. Oncology, 15, pp. 700-712 ;\n Lahoz-Beneytez, J., Elemans, M., Zhang, Y., Ahmed, R., Salam, A., Block, M., Macallan, D., Human neutrophil kinetics: Modeling of stable isotope labeling data supports short blood neutrophil half-lives (2016) Blood, 127, pp. 3431-3438 ;\n Lecot, P., Sarabi, M., Pereira Abrantes, M., Mussard, J., Koenderman, L., Caux, C., Michallet, M.C., Neutrophil heterogeneity in cancer: From biology to therapies (2019) Frontiers in Immunology, 10, p. 2155 ;\n Liao, W., Overman, M.J., Boutin, A.T., Shang, X., Zhao, D., Dey, P., DePinho, R.A., KRAS-IRF2 Axis drives immune suppression and immune therapy resistance in colorectal cancer (2019) Cancer Cell, 35. , (559-572.e557) ;\n Lin, C.-Y., Gustafsson, J.-Å., Targeting liver X receptors in cancer therapeutics (2015) Nature Reviews Cancer, 15, pp. 216-224 ;\n Liu, F.L., PoursineLaurent, J., Wu, H.Y., Link, D.C., Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation (1997) Blood, 90, pp. 2583-2590 ;\n Liu, Y., Wei, G., Cheng, W.A., Dong, Z., Sun, H., Lee, V.Y., Qin, H., Targeting myeloid-derived suppressor cells for cancer immunotherapy (2018) Cancer Immunology, Immunotherapy, 67, pp. 1181-1195 ;\n Liu, Y., Wei, J., Guo, G., Zhou, J., Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species (2015) Immunopharmacology and Immunotoxicology, 37, pp. 359-365 ;\n Lord, B.I., Molineux, G., Pojda, Z., Souza, L.M., Mermod, J.J., Dexter, T.M., Myeloid cell-kinetics in mice treated with recombinant Interleukin-3, granulocyte Colony-stimulating factor (Csf), or granulocyte-macrophage Csf Invivo (1991) Blood, 77, pp. 2154-2159 ;\n Lord, B.I., Woolford, L.B., Molineux, G., Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF) (2001) Clinical Cancer Research, 7, pp. 2085-2090 ;\n Lu, X., Horner, J.W., Paul, E., Shang, X., Troncoso, P., Deng, P., DePinho, R.A., Effective combinatorial immunotherapy for castration-resistant prostate cancer (2017) Nature, 543, pp. 728-732 ;\n Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Powles, T., TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells (2018) Nature, 554, pp. 544-548 ;\n Matlung, H.L., Babes, L., Zhao, X.W., van Houdt, M., Treffers, L.W., van Rees, D.J., van den Berg, T.K., Neutrophils kill antibody-opsonized cancer cells by Trogoptosis (2018) Cell Reports, 23 (3946-3959) ;\n Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Tabernero, J., Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer (2018) British Journal of Cancer, 119, pp. 1208-1214 ;\n Melisi, D., Hollebecque, A., Oh, D.Y., Calvo, E., Varghese, A.M., Borazanci, E.H., Garcia-Carbonero, R., A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) beta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer (2019) Journal of Clinical Oncology, 37 ;\n Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A.M., Frost, T.J., Gabrilovich, D.I., All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients (2006) Cancer Research, 66, pp. 9299-9307 ;\n Mishalian, I., Granot, Z., Fridlender, Z.G., The diversity of circulating neutrophils in cancer (2017) Immunobiology, 222, pp. 82-88 ;\n Moldogazieva, N.T., Mokhosoev, I.M., Feldman, N.B., Lutsenko, S.V., ROS and RNS signalling: Adaptive redox switches through oxidative/nitrosative protein modifications (2018) Free Radical Research, 52, pp. 507-543 ;\n Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., Viola, A., Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells (2011) Journal of Experimental Medicine, 208, pp. 1949-1962 ;\n Morris, J.C., Tan, A.R., Olencki, T.E., Shapiro, G.I., Dezube, B.J., Reiss, M., Lawrence, D.P., Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma (2014) PLoS One, 9 ;\n Morris, K.T., Castillo, E.F., Ray, A.L., Weston, L.L., Nofchissey, R.A., Hanson, J.A., Beswick, E.J., Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting NK cell, macrophage and T cell responses (2015) Oncotarget, 6, pp. 22338-22347 ;\n Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Gabrilovich, D.I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer (2007) Nature Medicine, 13, pp. 828-835 ;\n Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A.A., Gabrilovich, D.I., Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells (2007) Cancer Research, 67, pp. 11021-11028 ;\n Németh, T., Sperandio, M., Mócsai, A., Neutrophils as emerging therapeutic targets (2020) Nature Reviews. Drug Discovery ;\n Neugut, A.I., Lin, A., Raab, G.T., Hillyer, G.C., Keller, D., O'Neil, D.S., Hershman, D.L., FOLFOX and FOLFIRI use in stage IV colon cancer: Analysis of SEER-Medicare data (2019) Clinical Colorectal Cancer, 18, pp. 133-140 ;\n Nicolas-Avila, J.A., Adrover, J.M., Hidalgo, A., Neutrophils in homeostasis, immunity, and cancer (2017) Immunity, 46, pp. 15-28 ;\n Oklu, R., Sheth, R.A., Wong, K.H.K., Jahromi, A.H., Albadawi, H., Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis (2017) Cardiovasc Diagn Ther, 7, pp. S140-S149 ;\n Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Pili, R., Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma (2017) Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, pp. 5187-5201 ;\n Osipov, A., Saung, M.T., Zheng, L., Murphy, A.G., Small molecule immunomodulation: The tumor microenvironment and overcoming immune escape (2019) Journal for Immunotherapy of Cancer, 7 ;\n Ostrand-Rosenberg, S., Sinha, P., Beury, D.W., Clements, V.K., Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression (2012) Seminars in Cancer Biology, 22, pp. 275-281 ;\n Pan, P.-Y., Ma, G., Weber, K.J., Ozao-Choy, J., Wang, G., Yin, B., Chen, S.-H., Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer (2010) Cancer Research, 70, pp. 99-108 ;\n Papaspyridonos, M., Matei, I., Huang, Y.J., Andre, M.D., Brazier-Mitouart, H., Waite, J.C., Lyden, D., Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation (2015) Nature Communications, 6 ;\n Papayannopoulos, V., Neutrophil extracellular traps in immunity and disease (2018) Nature Reviews Immunology, 18, pp. 134-147 ;\n Park, J., Wysocki, R., Kessenbrock, K., Fein, M., Nakasone, E.S., Qiu, J., Egeblad, M., Cancer cells trigger neutrophils to induce metastasis-supporting extracellular DNA traps (2013) Molecular Biology of the Cell, 24 ;\n Patnaik, A., Swanson, K.D., Csizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M.P., Cantley, L.C., Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity (2017) Cancer Discovery, 7, pp. 750-765 ;\n Pinton, L., Solito, S., Damuzzo, V., Francescato, S., Pozzuoli, A., Berizzi, A., Mandruzzato, S., Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression (2016) Oncotarget, 7, pp. 1168-1184 ;\n Prima, V., Kaliberova, L.N., Kaliberov, S., Curiel, D.T., Kusmartsev, S., COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells (2017) Proceedings of the National Academy of Sciences of the United States of America, 114, pp. 1117-1122 ;\n van Raam, B.J., Drewniak, A., Groenewold, V., van den Berg, T.K., Kuijpers, T.W., Granulocyte colony-stimulating factor delays neutrophil apoptosis by inhibition of calpains upstream of caspase-3 (2008) Blood, 112, pp. 2046-2054 ;\n Raber, P.L., Thevenot, P., Sierra, R., Wyczechowska, D., Halle, D., Ramirez, M.E., Rodriguez, P.C., Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways (2014) International Journal of Cancer, 134, pp. 2853-2864 ;\n Righi, E., Kashiwagi, S., Yuan, J.P., Santosuosso, M., Leblanc, P., Ingraham, R., Poznansky, M.C., CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an Immunocompetent mouse model of ovarian cancer (2011) Cancer Research, 71, pp. 5522-5534 ;\n Rodriguez, P.C., Ochoa, A.C., Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives (2008) Immunological Reviews, 222, pp. 180-191 ;\n Rodriguez, P.C., Ochoa, A.C., Al-Khami, A.A., Arginine metabolism in myeloid cells shapes innate and adaptive immunity (2017) Frontiers in Immunology, 8, p. 93 ;\n Rodriguez, P.C., Quiceno, D.G., Ochoa, A.C., L-arginine availability regulates T-lymphocyte cell-cycle progression (2007) Blood, 109, pp. 1568-1573 ;\n Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., Ortiz, B., Zea, A.H., Piazuelo, M.B., Ochoa, A.C., Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses (2004) Cancer Research, 64, pp. 5839-5849 ;\n Rogers, N.C., Slack, E.C., Edwards, A.D., Nolte, M.A., Schulz, O., Schweighoffer, E., Reis e Sousa, C., Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins (2005) Immunity, 22, pp. 507-517 ;\n Rong, Y., Yuan, C.H., Qu, Z., Zhou, H., Guan, Q., Yang, N., Wang, F.B., Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2 (2016) Scientific Reports, 6, p. 23824 ;\n Sagiv, J.Y., Michaeli, J., Assi, S., Mishalian, I., Kisos, H., Levy, L., Granot, Z., Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer (2015) Cell Reports, 10, pp. 562-573 ;\n Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance (2008) Cell, 133, pp. 775-787 ;\n Schedin, P., Keely, P.J., Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression (2011) Cold Spring Harbor Perspectives in Biology, 3, p. a003228 ;\n Seliger, B., Relevance of the microenvironment and MHC class I mediated immune escape mechanisms of tumors for anti-tumoral immune responses (2017) Journal for Immunotherapy of Cancer, p. 5 ;\n Semerad, C.L., Liu, F.L., Gregory, A.D., Stumpf, K., Link, D.C., G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood (2002) Immunity, 17, pp. 413-423 ;\n Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Borrello, I., Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function (2006) The Journal of Experimental Medicine, 203, pp. 2691-2702 ;\n Seto, E., Yoshida, M., Erasers of histone acetylation: The histone deacetylase enzymes (2014) Cold Spring Harbor Perspectives in Biology, 6, p. a018713 ;\n Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential (2015) Cell, 161, pp. 205-214 ;\n Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy (2017) Cell, 168, pp. 707-723 ;\n Shojaei, F., Singh, M., Thompson, J.D., Ferrara, N., Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression (2008) Proceedings of the National Academy of Sciences of the United States of America, 105, pp. 2640-2645 ;\n Shojaei, F., Wu, X.M., Zhong, C.L., Yu, L.L., Liang, X.H., Yao, J., Ferrara, N., Bv8 regulates myeloid-cell-dependent tumour angiogenesis (2007) Nature, 450, pp. 825-U826 ;\n Sierra, M.D.L.L., Gasperini, P., McCormick, P.J., Zhu, J.F., Tosato, G., Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells (2007) Blood, 110, pp. 2276-2285 ;\n Sikalidis, A.K., Amino acids and immune response: A role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? (2015) Pathology Oncology Research, 21, pp. 9-17 ;\n Silvestre-Roig, C., Fridlender, Z.G., Glogauer, M., Scapini, P., Neutrophil diversity in health and disease (2019) Trends in Immunology, 40, pp. 565-583 ;\n Sinha, P., Clements, V.K., Bunt, S.K., Albelda, S.M., Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response (2007) Journal of Immunology, 179, pp. 977-983 ;\n Siolas, D., Vucic, E., Cullis, J., Choi, M., Bar-Sagi, D., Accumulation of neutrophils in the tumor microenvironment promotes resistance to immunotherapy in pancreatic cancer (2019) Cancer Research, 79 ;\n Spiegel, A., Brooks, M.W., Houshyar, S., Reinhardt, F., Ardolino, M., Fessler, E., Weinberg, R.A., Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells (2016) Cancer Discovery, 6, pp. 630-649 ;\n Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine (2010) Cancer Research, 70, pp. 68-77 ;\n Stevenson, J.P., Kindler, H.L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Albelda, S.M., Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients (2013) Oncoimmunology, 2 ;\n Stone, R.M., Maguire, M., Goldberg, M.A., Antin, J.H., Rosenthal, D.S., Mayer, R.J., Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: Experience in 34 patients (1988) Blood, 71, pp. 690-696 ;\n Sun, L., Clavijo, P.E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Allen, C.T., Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy (2019) JCI Insight, p. 4 ;\n Takahashi, R., Amano, H., Ito, Y., Eshima, K., Satoh, T., Iwamura, M., Majima, M., Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow (2020) Biomedicine & Pharmacotherapy, 121, p. 109581 ;\n Tauriello, D.V.F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Batlle, E., TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis (2018) Nature, 554, pp. 538-543 ;\n Tavazoie, D.V.F., Palomo-Ponce, I., Tanqucco, R., Ostendorf, B.N., Reis, B.S., Consalves, F.C., Tavazoie, S.F., LXR/ApoE activation restricts innate immune suppression in cancer (2018) Cell, 172, pp. 825-840 ;\n Tobin, R.P., Jordan, K.R., Robinson, W.A., Davis, D., Borges, V.F., Gonzalez, R., McCarter, M.D., Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab (2018) International Immunopharmacology, 63, pp. 282-291 ;\n Underhill, D.M., Rossnagle, E., Lowell, C.A., Simmons, R.M., Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production (2005) Blood, 106, pp. 2543-2550 ;\n Vansteenkiste, J.F., Van De Kerkhove, C., Wauters, E., Van Mol, P., Capmatinib for the treatment of non-small cell lung cancer (2019) Expert Review of Anticancer Therapy, 19, pp. 659-671 ;\n Veglia, F., Perego, M., Gabrilovich, D., Myeloid-derived suppressor cells coming of age (2018) Nature Immunology, 19, pp. 108-119 ;\n Veglia, F., Tyurin, V.A., Blasi, M., De Leo, A., Kossenkov, A.V., Donthireddy, L., Gabrilovich, D.I., Fatty acid transport protein 2 reprograms neutrophils in cancer (2019) Nature, 569, pp. 73-78 ;\n Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Ghiringhelli, F., 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity (2010) Cancer Research, 70, pp. 3052-3061 ;\n Waight, J.D., Netherby, C., Hensen, M.L., Miller, A., Hu, Q., Liu, S., Abrams, S.I., Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis (2013) Journal of Clinical Investigation, 123, pp. 4464-4478 ;\n Wang, G., Lu, X., Dey, P., Deng, P., Wu, C.C., Jiang, S., DePinho, R.A., Targeting YAP-dependent MDSC infiltration impairs tumor progression (2016) Cancer Discovery, 6, pp. 80-95 ;\n Wang, T.-T., Zhao, Y.-L., Peng, L.-S., Chen, N., Chen, W., Lv, Y.-P., Zou, Q.-M., Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway (2017) Gut, 66, pp. 1900-1911 ;\n Weed, D.T., Vella, J.L., Reis, I.M., De la Fuente, A.C., Gomez, C., Sargi, Z., Serafini, P., Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma (2015) Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21, pp. 39-48 ;\n Weed, D.T., Zilio, S., Reis, I.M., Sargi, Z., Abouyared, M., Gomez-Fernandez, C.R., Serafini, P., The reversal of immune exclusion mediated by Tadalafil and an anti-tumor vaccine also induces PDL1 Upregulation in recurrent head and neck squamous cell carcinoma: Interim analysis of a phase I clinical trial (2019) Frontiers in Immunology, 10, p. 1206 ;\n Whiteside, T.L., The tumor microenvironment and its role in promoting tumor growth (2008) Oncogene, 27, pp. 5904-5912 ;\n Wislez, M., Fleury-Feith, J., Rabbe, N., Moreau, J., Cesari, D., Milleron, B., Cadranel, J., Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma (2001) The American Journal of Pathology, 159, pp. 1423-1433 ;\n Wu, L., Saxena, S., Awaji, M., Singh, R.K., Tumor-associated neutrophils in cancer: going pro (2019) Cancers (Basel), p. 11 ;\n Xue, L.J., Mao, X.B., Ren, L.L., Chu, X.Y., Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma (2017) Cancer Medicine, 6, pp. 1424-1436 ;\n Yamamoto, H., Ehling, M., Kato, K., Kanai, K., van Lessen, M., Frye, M., Adams, R.H., Integrin beta1 controls VE-cadherin localization and blood vessel stability (2015) Nature Communications, 6, p. 6429 ;\n Yamauchi, Y., Safi, S., Blattner, C., Rathinasamy, A., Umansky, L., Juenger, S., Umansky, V., Circulating and tumor myeloid-derived suppressor cells in Resectable non-Small cell lung cancer (2018) American Journal of Respiratory and Critical Care Medicine, 198, pp. 777-787 ;\n Yan, G., Zhao, H., Zhang, Q., Zhou, Y., Wu, L., Lei, J., Li, Y., A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis (2018) Cancer Research, 78, pp. 5586-5599 ;\n Yang, P., Li, Y., Xie, Y., Liu, Y., Different faces for different places: Heterogeneity of neutrophil phenotype and function (2019) Journal of Immunology Research, 2019, p. 8016254 ;\n Youn, J.I., Kumar, V., Collazo, M., Nefedova, Y., Condamine, T., Cheng, P.Y., Gabrilovich, D.I., Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer (2013) Nature Immunology, 14, pp. 211-220 ;\n Zelenay, S., Van Der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Sousa, C., Cyclooxygenase-dependent tumor growth through evasion of immunity (2015) Cell, 162, pp. 1257-1270 ;\n Zeng, Y., Li, B.H., Liang, Y.Y., Reeves, P.M., Qu, X.Y., Ran, C.Z., Poznansky, M.C., Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment (2019) FASEB Journal, 33, pp. 6596-6608 ;\n Zhang, P., Iwama, A., Datta, M.W., Darlington, G.J., Link, D.C., Tenen, D.G., Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis (1998) Journal of Experimental Medicine, 188, pp. 1173-1184 ;\n Zhou, J., Nefedova, Y., Lei, A.H., Gabrilovich, D., Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells (2018) Seminars in Immunology, 35, pp. 19-28 ;\n Zigrino, P., Ayachi, O., Schild, A., Kaltenberg, J., Zamek, J., Nischt, R., Mauch, C., Loss of epidermal MMP-14 expression interferes with angiogenesis but not with re-epithelialization (2012) European Journal of Cell Biology, 91, pp. 748-756 ;\n Zou, W., Regulatory T cells, tumour immunity and immunotherapy (2006) Nature Reviews. Immunology, 6, pp. 295-307", "hasCitationDuplums" : false, "userChangeableUntil" : "2020-08-10T17:39:26.021+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 2, "ownerInstituteCount" : 15, "directInstituteCount" : 0, "authorCount" : 5, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31310604", "label" : "Zhao Y. et al. Rational targeting of immunosuppressive neutrophils in cancer. (2020) PHARMACOLOGY & THERAPEUTICS 0163-7258 1879-016X 212", "template" : "